title: [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
abstract: A 68-year-old man complained of dizziness and was referred to our hospital by his primary physician for evaluation of an elevated leukocyte count. In April 2002, soon after the chronic phase of chronic myeloid leukemia had been diagnosed, he was treated with imatinib. In March 2010, imatinib treatment was completed and the BCR/ABL fusion gene had become undetectable by real time quantitative PCR. Subsequently, leukocyte counts and the hematocrit gradually rose. In August 2012, a bone marrow aspirate showed hypercellular marrow with marked erythroid hyperplasia and the presence of the JAK2 gene V617F mutation. He was diagnosed with polycythemia vera. Phlebotomy and chemotherapy were started in addition to imatinib administration. Shortly thereafter complete blood counts returned to normal levels.
authors.affiliation: Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital.
authors.forename: Wataru
authors.initials: W
authors.lastname: Jomen
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Teppei
authors.initials: T
authors.lastname: Matsuno
authors.forename: Masanori
authors.initials: M
authors.lastname: Sato
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Abe
authors.forename: Tamaki
authors.initials: T
authors.lastname: Sakurai
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Maeda
authors.forename: Miri
authors.initials: M
authors.lastname: Fujita
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
authors.forename: Shuichi
authors.initials: S
authors.lastname: Nojiri
mesh_terms: D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006400:Hematocrit; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D007958:Leukocyte Count; D008297:Male; D009154:Mutation; D018962:Phlebotomy; D010879:Piperazines / Q000627:therapeutic use*; D011087:Polycythemia Vera / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D011743:Pyrimidines / Q000627:therapeutic use*; D060888:Real-Time Polymerase Chain Reaction; D012074:Remission Induction
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2